(1) Validation of the benefits of the DreamWear mask. Satisfaction assessment survey carried out in France between November 2015 and March 2017 with 300 patients treated with CPAP wearing the DreamWear mask and 52 doctors
(2) from Ortho et al. ; Perception study of a new generation auto CPAP device (N ° ISRCTN50028060); 2015 ; prospective, multicenter study where the patient is his own witness (before-after). The 107 included patients treated with self-controlled CPAP for at least 3 hours per night (machine compliance report) tested the PR1 P-Flex for 7 days. 83% of patients prefer PR1 P-Flex to their previous CPAP (p <0.001).
(3) Codron F. et al. ; Auto CPAP validation study with P-Flex comfort mode (ISRCTN84084377); 2014 ; The 38 patients included have newly diagnosed OSAH with an AHI of at least 30 / h. The patients are fitted by CPAP with the P-Flex mode. The CPAP treatment with the auto REMstar PR1 with the P-Flex comfort mode was well tolerated and accepted by the patients throughout the 3 months of the study. The correction of OSAHS was perfectly obtained by this mode with lower treatment pressures and accompanied by a significant decrease in the ESE score (14 to 6.6-p <0.001).
(4) Declared two-digit noise emission values. In accordance with ISO 4871
The A-weighted emission sound pressure level is:
· Device: 25.8 dB (A) with an uncertainty of 2 dB (A).
· Device with humidifier: 27.9 dB (A) with an uncertainty of 2 dB (A).
The A-weighted emission sound power level is:
· Device: 33.8 dB (A) with an uncertainty of 2 dB (A).
Device with humidifier: 35.9 dB (A) with an uncertainty of 2 dB (A). 26
Note: Values determined in accordance with the noise test code provided in ISO 80601-2-70: 2015, using the basic ISO 3744 and ISO 4871 standards.
(5) Hardy W. et al. ; Retrospective naturalistic study involving 172,679 patients, based on records extracted from the EncoreAnywhere database (dates of registration on EncoreAnywhere between March 1, 2013 and January 1, 2016); After 90 days, patients using DreamMapper achieved a 78% adherence rate, while patients not using DreamMapper had a 63% adherence rate. Patients using DreamMapper also received the treatment for 1.1 hours longer per night on average compared to those not using DreamMapper. DreamMapper also helped patients who had difficulty starting treatment. 46% of those who struggled and used DreamMapper managed to become diligent in 90 days, compared to just 12% of those who did not have DreamMapper.
(6) Martínez-García MA et al., Effect of CPAP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPARCO randomized clinical trial. JAMA. 2013 Dec 11;310(22):2407-15. doi : 10.1001 / jama.2013.281250
Patient testimonials are experiences specific to each of them. However, other patients think like them or the data collected makes it possible to make these testimonials objective:
(7) Nussbaumer Yet al., Equivalence of Autoadjusted and Constant Continuous Positive Airway Pressure in Home Treatment of Sleep Apnea. Chest. 2006 Mar;129(3):638-43.
(8) Ramar K. et al, Clinical Practice Guideline for the Treatment of Obstructive Sleep Apnea and Snoring with Oral Appliance Therapy: An Update for 2015. J Clin Sleep Med. 2015 Jul 15;11(7):773-827. doi : 10.5664/jcsm.4858.
(9) “Satisfaction assessment survey carried out in France between November 2015 and March 2017 with 300 patients treated with CPAP wearing the DreamWear mask and 52 doctors.” [jugé confortable par 38% des patients interrogés, NPS de +19] + [ne laisse pas de traces sur le visage pour 78% des patients interrogés, NPS de +28] + [jugé bien perçu par le conjoint pour 26% des patients interrogés, NPS de +4]